The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Global, regional, and national burden of gout, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021
Open accessAbstract
BACKGROUND: Gout is an inflammatory arthritis manifesting as acute episodes of severe joint pain and swelling, which can progress to chronic tophaceous or chronic erosive gout, or both. Here, we present the most up-to-date global, regional, and national estimates for prevalence and years lived with disability (YLDs) due to gout by sex, age, and location from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, as well as forecasted prevalence to 2050. METHODS: Gout prevalence and YLDs from 1990 to 2020 were estimated by drawing on population-based data from 35 countries and claims data from the USA and Taiwan (province of China). Nested Bayesian meta-regression models were used to estimate prevalence and YLDs due to gout by age, sex, and location. Prevalence was forecast to 2050 with a mixed-effects model. FINDINGS: In 2020, 55·8 million (95% uncertainty interval 44·4-69·8) people globally had gout, with an age-standardised prevalence of 659·3 (525·4-822·3) per 100 000, an increase of 22·5% (20·9-24·2) since 1990. Globally, the prevalence of gout in 2020 was 3·26 (3·11-3·39) times higher in males than in females and increased with age. The total number of prevalent cases of gout is estimated to reach 95·8 million (81·1-116) in 2050, with population growth being the largest contributor to this increase and only a very small contribution from the forecasted change in gout prevalence. Age-standardised gout prevalence in 2050 is forecast to be 667 (531-830) per 100 000 population. The global age-standardised YLD rate of gout was 20·5 (14·4-28·2) per 100 000 population in 2020. High BMI accounted for 34·3% (27·7-40·6) of YLDs due to gout and kidney dysfunction accounted for 11·8% (9·3-14·2). INTERPRETATION: Our forecasting model estimates that the number of individuals with gout will increase by more than 70% from 2020 to 2050, primarily due to population growth and ageing. With the association between gout disability and high BMI, dietary and lifestyle modifications focusing on bodyweight reduction are needed at the population level to reduce the burden of gout along with access to interventions to prevent and control flares. Despite the rigour of the standardised GBD methodology and modelling, in many countries, particularly low-income and middle-income countries, estimates are based on modelled rather than primary data and are also lacking severity and disability estimates. We strongly encourage the collection of these data to be included in future GBD iterations. FUNDING: Bill & Melinda Gates Foundation and the Global Alliance for Musculoskeletal Health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Self-citationMurray, C. J. L., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30752-2 · Cited by 9,854
Self-citationBikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Self-citationWang, H., Abbas, K. M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., Abolhassani, H., Abreu, L. G., Abrigo, M. R. M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30977-6 · Cited by 1,971
Self-citationVollset, S. E., Goren, E., Yuan, C.-W., Cao, J., Smith, A. E., Hsiao, T., Bisignano, C., Azhar, G. S., Castro, E., Chalek, J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30677-2 · Cited by 1,506
Self-citationPreliminary criteria for the classification of the acute arthritis of primary gout
Wallace, S. L., Robinson, H., Masi, A. T., Decker, J. L., Mccarty, D. J., & Yü, T. (1977) · Arthritis & Rheumatism · doi:10.1002/art.1780200320 · Cited by 1,432
Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors
Dehlin, M., Jacobsson, L., & Roddy, E. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0441-1 · Cited by 1,370
Dalbeth, N., Gosling, A. L., Gaffo, A., & Abhishek, A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00569-9 · Cited by 1,338
Global epidemiology of gout: prevalence, incidence and risk factors
Kuo, C.-F., Grainge, M. J., Zhang, W., & Doherty, M. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.91 · Cited by 1,179
Comorbidities of Gout and Hyperuricemia in the US General Population: NHANES 2007-2008
Zhu, Y., Pandya, B. J., & Choi, H. K. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.09.033 · Cited by 655
Cited by
Du, K., Li, A., Zuo, Q.-H., Zhang, C.-Y., Guo, R., Chen, P., Du, W.-S., & Li, S.-M. (2025) · Journal of Medical Internet Research · doi:10.2196/67830 · Cited by 24
Metadata
- Authors
- Cross, M., Ong, K. L., Culbreth, G. T., Steinmetz, J. D., Cousin, E., Lenox, H., Kopec, J. A., Haile, L. M., Brooks, P. M., Kopansky-Giles, D. R., Dreinhoefer, K. E., Betteridge, N., Abbasian, M., Abbasifard, M., Abedi, A., Aboye, M. B., Aravkin, A. Y., Artaman, A., Banach, M., Bensenor, I. M., Bhagavathula, A. S., Bhat, A. N., Bitaraf, S., Buchbinder, R., Burkart, K., Chu, D.-T., Chung, S.-C., Dadras, O., Dai, X., Das, S., Dhingra, S., Do, T. C., Edinur, H. A., Fatehizadeh, A., Fetensa, G., Freitas, M., Ganesan, B., Gholami, A., Gill, T. K., Golechha, M., Goleij, P., Hafezi-Nejad, N., Hamidi, S., Hay, S. I., Hundessa, S., Iso, H., Jayaram, S., Kadashetti, V., Karaye, I. M., Khan, E. A., Khan, M. A., Khatatbeh, M. M., Kiadaliri, A., Kim, M. S., Kolahi, A.-A., Krishan, K., Kumar, N., Le, T. T. T., Lim, S. S., Lobo, S. W., Majeed, A., Malik, A. A., Mesregah, M. K., Mestrovic, T., Mirrakhimov, E. M., Mishra, M., Misra, A. K., Moberg, M. E., Mohamed, N. S., Mohan, S., Mokdad, A. H., Momenzadeh, K., Moni, M. A., Moradi, Y., Mougin, V., Mukhopadhyay, S., Murray, C. J. L., Narasimha Swamy, S., Nguyen, V. T., Niazi, R. K., Owolabi, M. O., Padubidri, J. R., Patel, J., Pawar, S., Pedersini, P., Rafferty, Q., Rahman, M., Rashidi, M.-M., Rawaf, S., Saad, A. M. A., Sahebkar, A., Saheb Sharif-Askari, F., Saleh, M. A., Schumacher, A. E., Seylani, A., Singh, P., Smith, A. E., Solanki, R., Solomon, Y., Tan, K.-K., Tat, N. Y., Tibebu, N. S. S., You, Y., Zheng, P., Zitoun, O. A., Vos, T., March, L. M., & Woolf, A. D.
- Venue
- The Lancet Rheumatology
- Publisher
- Elsevier BV
- Published
- 2024-08
- Volume
- 6
- Issue
- 8
- Pages
- e507-e517
- ISSN
- 2665-9913 (ISSN-L)
- OpenAlex
- W4400439918
- Cited by
- 313
- References
- 32
- FWCI
- 77.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Global, regional, and national burden of gout, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. https://app.cochat.ai/papers/10.1016/s2665-9913(24)00117-6
- The paper
- Cross, M., Ong, K. L., Culbreth, G. T., Steinmetz, J. D., Cousin, E., Lenox, H., Kopec, J. A., Haile, L. M., Brooks, P. M., Kopansky-Giles, D. R., Dreinhoefer, K. E., Betteridge, N., Abbasian, M., Abbasifard, M., Abedi, A., Aboye, M. B., Aravkin, A. Y., Artaman, A., Banach, M., . . . Woolf, A. D. (2024). Global, regional, and national burden of gout, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. The Lancet Rheumatology. https://doi.org/10.1016/s2665-9913(24)00117-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.